Neo Ivy Capital Management grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 512.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 297,627 shares of the biotechnology company's stock after buying an additional 249,043 shares during the period. ADMA Biologics accounts for 1.0% of Neo Ivy Capital Management's investment portfolio, making the stock its 15th largest holding. Neo Ivy Capital Management owned about 0.13% of ADMA Biologics worth $5,104,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics in the 4th quarter worth $19,076,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after acquiring an additional 2,613,482 shares in the last quarter. Veracity Capital LLC increased its holdings in ADMA Biologics by 117.0% during the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after acquiring an additional 25,030 shares in the last quarter. Nkcfo LLC purchased a new position in ADMA Biologics during the 4th quarter valued at about $325,000. Finally, JPMorgan Chase & Co. increased its holdings in ADMA Biologics by 272.5% during the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after acquiring an additional 561,310 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Analysts Set New Price Targets
ADMA has been the subject of several recent research reports. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ADMA Biologics presently has an average rating of "Moderate Buy" and a consensus price target of $24.25.
Get Our Latest Analysis on ADMA
ADMA Biologics Trading Up 0.2%
Shares of ADMA opened at $20.16 on Friday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.81 billion, a P/E ratio of 72.00 and a beta of 0.57. The stock's fifty day simple moving average is $20.64 and its 200 day simple moving average is $18.91. ADMA Biologics, Inc. has a twelve month low of $9.35 and a twelve month high of $25.67.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 earnings per share. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
